However, anticancer drugs activated by NRF2-induced enzymes such as NQO1 [60] could be exploited in SOCS1-low/SOCS3-high HCC and other instances of NRF2-mediated cancer progression. The gene discussed is NFE2L2; the disease is hepatocellular carcinoma.